Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Agilent Technologies Gets European Certification For PD-L1 IHC 22C3 PharmDx To Help Gastric Or GEJ Adenocarcinoma Patients for KEYTRUDA Therapy
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Bluebird Bio Announces That After Three Weeks Of Engagement, Ayrmid Has Not Submitted A Binding Proposal To Acquire Bluebird And Has Not Obtained Necessary Financing
Carlyle, SK Capital Partners, And Beacon Parent Holdings Announced That Beacon Merger Sub, Inc. Has Extended The Expiration Date Of Its Offer To Acquire All Of The Outstanding Common Stock Of Bluebird Bio, To Expire At One Minute After 11:59 P.M., New...
Green Plains Adds Three New Board Members; BofA Downgrades on Macro Headwinds